Phenylbutazone ("Butazolidin") is an effective therapeutic agent in acute gouty arthritis (Kuzell and co-workers, 1952, 1954; Kidd, Boyce, and Freyberg, 1952, 1953; Stephens, Yeoman, Holbrook, Hill, and Goodin, 1952; Steinbrocker, Berkowitz, Ehrlich, Elkind, and Carp, 1952; Engleman, Krupp, Forsham, Griffin, Johnson, Green, and Goldfien, 1953) . It is a synthetic pyrazol derivative, with the chemical designation 3,5-dioxo-1,2-diphenyl-4-nbutylpyrazolidine. In this clinic, 21 (1952, 1954) and Kidd and others (1953) have reported that the drug has no effect on the excretion of urate. Johnson and others (1954) It has been noted that in gouty patients the elevated plasma urate level generally falls to normal or almost normal shortly after the administration of phenylbutazone. Kidd and others (1952) determined the change in the plasma urate values in fifteen patients with gout and found the average decrease to be 3-5 mg. per cent.; in thirteen nongouty patients who had been receiving phenylbutazone, the average decrease was 12 mg. per cent. The mechanism of this decrease was not established. Kuzell and others (1952, 1954) state that, although the uric acid values in the serum promptly fell after the use of phenylbutazone, there was no consistent increase in the urinary excretion coincident with decrease in serum uric acid. Kidd and others (1952), in a study of nine patients with uncontrolled diets, observed no significant increase in output of urinary urate, they suggested that the decrease in plasma concentration of uric acid may not be due to a uricosuric action of this drug. In preliminary studies reported from this laboratory Huffman and others, 1953) results were obtained contrary to these observations.
4 days and noted a fall in the serum urate concentration with a reduction in the urine urate. Mason (1954) reported that phenylbutazone had a uricosuric effect in three out of four cases of gout and in one subject with Paget's disease of the bone. In our experience, phenylbutazone causes an increase in urate excretion. The observations which form the basis for this report are in agreement with those of Yu, Sirota, and Gutman (1953) , who demonstrated a definite increase in the renal clearance of urate in gouty subjects during short-term infusion experi- ments as well as an increased 24-hr urinary urate excretion after oral administration of phenylbutazone.
It has been noted that in gouty patients the elevated plasma urate level generally falls to normal or almost normal shortly after the administration of phenylbutazone. Kidd and others (1952) determined the change in the plasma urate values in fifteen patients with gout and found the average decrease to be 3-5 mg. per cent.; in thirteen nongouty patients who had been receiving phenylbutazone, the average decrease was 12 mg. per cent. The mechanism of this decrease was not established. Kuzell and others (1952, 1954) state that, although the uric acid values in the serum promptly fell after the use of phenylbutazone, there was no consistent increase in the urinary excretion coincident with decrease in serum uric acid. Kidd and others (1952) , in a study of nine patients with uncontrolled diets, observed no significant increase in output of urinary urate, they suggested that the decrease in plasma concentration of uric acid may not be due to a uricosuric action of this drug. In preliminary studies reported from this laboratory Huffman and others, 1953) results were obtained contrary to these observations.
Methods
It was the purpose of this study to obtain information on the effect of phenylbutazone on the serum urate levels and the 24-hr excretion of urinary urate. The uricosuric effect of different serum levels of this drug administered orally was determined.
Daily serum and urinary uric acid levels were determined according to the method reported by Forsham and others (1948) The mean change in the 24-hr urinary urate excretion in the non-gouty subjects was less marked and not significant when analysed by the same statistical method. The mean increase for the nine studies in the non-gouty subjects during the period of phenylbutazone administration was 69 mg., an increase of 12 per cent. over the mean control value. The positive change over control values expressed in percentage variation was 3 to 60 in seven out of nine instances. Cases 11 and 16, having a mean excretion less than the control, developed objective manifestations of fluid retention. Case 10 had a mean excretion increase of 3 per cent. while receiving 400 mg. phenylbutazone daily with a resulting serum phenylbutazone level of 9 mg. per cent.
The response of Case 2 (a patient with gout) to a daily dose of 800 mg. phenylbutazone is illustrated in Fig. 1 . The serum uric acid values were between 7-2 and 8-0 mg. per cent. during the three control days. There was a progressive and stepwise fall of the serum urate, beginning after the first day of therapy and reaching the maximum decrease after the sixth day. The urinary excretion of uric acid increased in a corresponding stepwise fashion and reached a maximum on the sixth day of study. It will be noted that in this particular study the phenylbutazone blood level increased gradually during the first 6 days of treatment and then levelled off at approximately 15 mg. per cent. The maximum effect upon the serum level corresponds closely to the maximum blood level of the drug. The average total fall in serum urate to 4-6 mg. per cent. was reached by the eighth day. The response in this case is typical of the changes observed in both the gouty and non-gouty patients. Fig. 2 shows a similar study in a non-gouty arthritic (Case 10) receiving 800 mg. phenylbutazone daily. Although the magnitude of the changes is not as great as in the patients with gout, the pattern is the same. The serum phenylbutazone level reached a plateau on the fifth day, at which time the serum uric acid level reached the lowest level and remained relatively constant for the duration of therapy. Urinary uric acid excretion reached its peak on the fourth day of therapy.
Urate Clearance. The effect of oral phenylbutazone on the renal clearance of urate was studied in three gouty and five non-gouty subjects (Table II,  overleaf) .
Simultaneous endogenous creatinine and urate clearances were determined before treatment and repeated after 8 days of therapy. Preliminary studies demonstrated that further significant change in the serum or urinary uric acid seldom occurred The creatinine clearance under therapy decreased in both groups; falling from 85 to 76 7 ml./min. in the gouty subjects and from 102-5 to 100 5 ml./min. in the non-gouty. All subjects, both gouty and nongouty, had an increase in the Clearance Urate: Clearance Creatinine ratio (Cur: Ccr). In gouty subjects the mean Cur: Cer rose from 0 049 to 0-173 (increase of 257-1 per cent.). In the nongouty subjects the ratio rose from 0-071 to 0-156 (increase of 15 0 per cent.). In the gouty subjects, the mean percentile change ranged from 33 to 497 7; in the non-gouty from 30-1 to 198 0.
The (Brock, 1953) have shown that by the eighth day on any given dosage, the serum phenylbutazone has reached a constant level which is unaltered by further administration of the same dosage of the drug. It is apparent from Fig. 3 All but three of thirteen patients receiving 600 mg. and all the patients receiving 800 mg. or above daily had serum levels above 10 mg. per cent. Figs 1 and 2 demonstrate the rate of increase of serum phenylbutazone when a patient is started on a daily oral intake of 800 mg. The pattern of response is similar for all dosages, but the rate of increase varies for different dosages. All of five patients receiving dosages of 800 mg. daily or above had serum levels in excess of 10 mg. per cent. by the third day. On the contrary, in four patients receiving 600 mg. daily, a 10 mg. per cent. level was not reached until the 6th day. The serum response to any given daily oral intake of phenylbutazone varied considerably. The range of variation for all doses averaged 6 mg. per cent. After cessation of therapy there was a gradual decline in the serum level over a 7-to 14-day period.
Discussion
The observations reported in this paper would add phenylbutazone to the list of substances which alter the urate tubular transport mechanism. The increased excretion of urate is contrary to the reports of others (Kuzell and others, 1952, 1954; Kidd, Boyce, and Freyberg, 1953; Johnson and others, 1954; Mason, 1954) and in accord with the work of YO, Sirota, and Gutman (1953) . The studies herein presented have demonstrated in both gouty and non-gouty arthritics a consistent fall in the serum uric acid, an increased clearance of uric acid, and in the gouty subjects a significant increase in 24-hr urate excretion. The mean 24-hr urinary urate excretion for the non-gouty subjects, while not statistically significant, did rise in seven out of nine instances. In both groups, all subjects except Case 9 had single 24-hr urinary excretions of urate which exceeded the control value, and preceded (in sixteen out of nineteen instances) the maximum fall in the serum urate.
It is evident from this data that the alteration in renal function is one of the major mechanisms responsible for the decrease in the serum urate in gouty subjects. The fact that in one gouty and two non-gouty subjects the serum urate level fell while the mean 24-hr urate excretion did not rise, indicates that other mechanisms are at work in decreasing the serum urate level during phenylbutazone therapy. Indeed, Delfel and Griffin (1953) , studying the effect of phenylbutazone on rat liver homogenate, reported that the drug apparently decreased the catabolism of nucleic acid. Further, it has been shown that phenylbutazone increases the blood volume (Wilkinson and Brown, 1953; Brodie and others, 1954) , thus causing a decrease due to dilution of the serum urate. It is to be noted that all three of the subjects in whom the serum urate fell without a corresponding increase in the urinary urate developed oedema and other manifestations of fluid retention. Fluid retention would appear to explain some of reported observations of the effect of phenylbutazone on serum urate. Johnson and others (1954) studied two patients who were given 1,000 mg. of the drug daily, and manifested considerable suppression of all the urinary constituents studied: 24-hr volume, creatinine, urate, sodium, and 17-hydroxy-corticoids. The diversity of substances affected suggests that a general mechanism, such as fluid retention, is responsible for the serum urate change. Mason (1954) noted that, where water retention did not supervene, a marked uricosuric action was effected by the drug. He concluded that phenylbutazone had a slight uricosuric effect and also a salt-and-water retaining effect. Kuzell and others (1952, 1954) Phenylbutazone caused an increased clearance of serum urate in both gouty and non-gouty subjects. The data presented here supports the conclusion of Yu, Sirota, and Gutman (1953) that serum phenylbutazone levels above 10 mg. per cent. are necessary to produce a significant increase in the clearance of urate. They noted in short-term infusion experiments that serum phenylbutazone levels below 10 mg. per cent. did not significantly increase urate clearance. The subjects in this study with serum phenylbutazone levels below 10 mg. per cent. had an increase in the Cur: Ccr ratio of 48 per cent., compared with 345 per cent. in those with drug levels above 10 mg. per cent.
While serum levels of phenylbutazone above 10 mg. per cent. are necessary to obtain a marked increase in the clearance of urate, it would appear that this drug may be useful as a uricosuric agent. A daily intake of 600 mg. or more is necessary to bring about a serum phenylbutazone level of 10 mg. per cent. or above. Since in our experience the incidence of toxicity of patients receiving oral phenylbutazone on dosages above 600 mg. per cent. is greatly increased, this limits the clinical use of this drug as a long-term uricosuric agent. (6) Dosages above 600 mg./24 hrs are necessary to obtain a consistent uricosuric effect.
(7) Acute attacks of gout are aborted at serum levels insufficient to cause a uricosuric effect.
(8) On a regular daily oral dose, serum phenylbutazone levels reach a plateau between the sixth and eighth day of therapy and remain relatively constant thereafter.
The phenylbutazone used in these studies was supplied by the Geigy Pharmaceuticals Inc., of New York, through the courtesy of Dr. Albert Hemming to whom we express our appreciation. The authors gratefully acknowledge the co-operation given this project by the nursing and dietetic departments of the Veterans Administration Hospital, Denver, Colorado. 32, 1121. Effet m6tabolique de la ph~nylbutazone dans l'arthrite goutteuse et non-goutteuse REsuME (1) La phenylbutazone est un agent therapeutique efficace contre l'attaque aigue de goutte.
(2) Administree par voie buccale, la ph6nylbutazone est un agent uricosurique.
(3) La chute de l'acide urique dans le serum, produite par la phenylbutazone chez les goutteux, correspond A son excretion urinaire augmentee.
(4) Trois malades dans cette serie manifesterent une chute sanguine des urates accompagnee de leur baisse excretoire moyenne par 24 heures. Chez tous les malades on observa une retention aqueuse marque, ce qui semble jouer un r6le dans la baisse de la concentration sanguine des urates.
(5) L'effet uricosurique est nettement demontrable aux taux seriques de la phenylbutazone au-dessus de 10 mg. pour cent.
